Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1,413 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:09 PM 10/1/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY*) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/15 - $1,480
52 Week Low
10/17/14 - $840.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY*)

eli lilly & co (LLY*) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. It has collaboration agreement with ZP Opco, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY*) Key Developments

Zosano Dissolves Licensing Partnership with Eli Lilly for ZP-PTH

Zosano Pharma (US) has announced it will stop developing the daily version of its ZP-PTH candidate treatment for severe osteoporosis and instead resume development of the weekly version. The company said its decision was prompted by feedback from Japanese regulatory authorities that they would require additional studies that would be likely to delay commercialisation in Japan by about a year. Zosano's licensing partnership with Eli Lilly (US) for ZP-PTH has therefore been dissolved. Zosano has discontinued its development of daily ZP-PTH despite reportedly receiving positive feedback from the US FDA and it had been on course to initiate a Phase III programme in the United States. In light of the feedback from the Japanese authorities, however, Zosano believes its resources would be more prudently deployed by focusing on weekly ZP-PTH, for which it is planning to initiate a Phase II trial in the first half of 2016. Zosano had entered into its partnership with Lilly in late 2014.

Adocia and Eli Lilly and Company Initiate New Phase 1b Study of Repeat Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 2 Diabetes

Adocia and Eli Lilly and Company announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, to accelerate insulin absorption. This study, under the Adocia-Lilly partnership, aims to measure the effect of BioChaperone Lispro injected at mealtime on post-meal glycemic control in type 2 diabetes patients compared to that of Humalog® (insulin lispror DNA origin) over the same two-week period. Commercialized fast-acting insulin analogs are usually injected before the meal. An ultra-rapid insulin aims to allow injection at the time of the meal, or even after the start of a meal, with the goal of reducing the magnitude of glycemic excursions. The first clinical study conducted by the two companies demonstrated that BioChaperone Lispro was associated with a 61% reduction in post-prandial glucose excursions over the first two hours post-meal compared to Humalog. This new clinical study is designed to document the potential benefit of BioChaperone Lispro in patients with type 2 diabetes, a population representing about 90% of people living with diabetes. In this crossover, randomized, double-blind study, 50 subjects with type 2 diabetes will receive multiple daily doses of BioChaperone Lispro and multiple daily doses of Humalog over two periods of 14 days each. The main objective of this study is to compare the post-meal glycemic control obtained after the injection of either BioChaperone Lispro or Humalog immediately before the meal. The pharmacokinetic profiles of both products will also be monitored. This study will be sponsored by Adocia, and performed by Profil Neuss in Germany.

Eli Lilly and Company and Incyte Corporation Announce Positive Results of RA-BEGIN Study

Eli Lilly and Company and Incyte Corporation announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response rate after 24 weeks of treatment. Additionally, baricitinib was superior to methotrexate based on ACR20 response. The RA-BEGIN study included patients who had limited or no prior treatment with methotrexate, and were naïve to other conventional or biologic disease-modifying antirheumatic drugs (DMARDs). Part of a larger Phase 3 program of more than 3,000 RA patients at various points in the RA treatment continuum, RA-BEGIN enrolled nearly 600 patients who were randomized to one of the following treatment groups: Once-weekly oral methotrexate monotherapy; 4 mg once-daily oral baricitinib monotherapy; 4 mg once-daily oral baricitinib in combination with once-weekly oral methotrexate. In RA-BEGIN, the incidence of treatment-emergent adverse events and serious adverse events, including serious infections, was similar across treatment groups. No cases of tuberculosis or gastrointestinal perforation were reported during the study. The most common adverse events observed were consistent with previous studies of baricitinib in RA. Discontinuations due to adverse events were more common in patients receiving the combination of baricitinib plus methotrexate. A large majority of patients completing RA-BEGIN opted to participate in a long-term extension study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY*:MM $1,412.58 MXN 0.00

LLY* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.08 USD -1.60
Allergan plc $272.88 USD -5.70
Amgen Inc $141.22 USD 0.00
Bristol-Myers Squibb Co $59.88 USD 0.00
Medtronic PLC $69.92 USD -0.95
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY* Industry Range
Price/Earnings 44.9x
Price/Sales 4.7x
Price/Book 6.3x
Price/Cash Flow 46.6x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at